Otros idiomas Immuneering Corporation

Acciones

IMRX

US45254E1073

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:01 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1,64 ^USD	+5,13 %		+11,56 %	-77,69 %

09/04	Immuneering Corporation presenta datos preclínicos en la Reunión Anual de la Asociación Americana para la Investigación del Cáncer	CI
02/04	IMMUNEERING CORPORATION : Mizuho Securities da una recomendación de compra	ZM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models	09/04
Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	09/04
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference	03/04
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	27/03
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	27/03
Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations	27/03
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI	20/03
North American Morning Briefing : Investors -2-	18/03
Sector Update: Health Care Stocks Ease Late Afternoon	15/03
Sector Update: Health Care	15/03
Immuneering Shares Decline After Analysts Downgrades, Phase 1 Cancer Therapy Data	15/03
North American Morning Briefing : Inflation -2-	15/03
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	14/03
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	14/03
Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors	14/03
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors	12/03
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors	12/03
Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors	12/03
Immuneering Begins Phase 2a Testing of Potential Cancer Immunotherapy; Phase 1 Data Due Out Soon	11/03
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors	11/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Immuneering Corporation

Acciones

IMRX

US45254E1073

Otros idiomas

Filtros